How to define treatment failure for JAK inhibitors

Affiliations

Comment

Hans Michael Kvasnicka. Lancet Haematol. 2017 Jul.

. 2017 Jul;4(7):e305-e306.

doi: 10.1016/S2352-3026(17)30102-3. Epub 2017 Jun 8.

¹ Senckenberg Institute of Pathology, University of Frankfurt, Frankfurt, 60590, Germany. Electronic address: hans-michael.kvasnicka@kgu.de.

No abstract available

Comment on

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA. Harrison CN, et al. Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8. Lancet Haematol. 2017. PMID: 28602585 Free PMC article. Clinical Trial.